2024 Letter from the CEO
Time for some end of year reflection. It’s been a year of rapid progress, deep learning, as well as excitement at Gaize, and I’d like to share some of it with you all.
First, I’m immensely proud of the team at Gaize and the solution we’ve built. It’s very clearly the right product for those who need to detect active impairment from drugs and alcohol. Today, Gaize is deployed in a wide variety of businesses and several law enforcement agencies. That’s incredible, but the clearest signal for success to me today is that the product has rapidly become a mission-critical piece of technology for our customers. I’d like to extend my warmest appreciation to those leaders who have purchased and deployed Gaize in their organizations. We’re 100% committed to you and your success.
Since 2023 was the year we officially launched the product, we hit the road and got the word out. Gaize staff participated in many great events this year, including green labs, conferences, trade shows, and meetings of trade groups. We’ve enjoyed face-time with congressional representatives, law enforcement leadership and executives with some of the world’s largest companies. We're excited and encouraged by the great field work and research that's being conducted with our friends and partners in states like Maryland and Missouri. Gaize is fortunate to have established relationships with leading organizations working to build and maintain safety in driving and working. We hope maintaining open dialogue with other states such as Minnesota, California and New York will yield broader discussions in an effort to solve the publicly stated challenge of drug impairment detection.
Jurisdictions with legal access to cannabis and other drugs are facing an acute challenge in the need to detect active impairment from these substances, rather than just prior use. Whereas simple presence of THC in the body was once a crime, the majority of the US population now has legal access to cannabis. Law enforcement and businesses in those places must evolve away from the legacy tests that simply look for the presence of a drug because, unlike alcohol, the presence of a drug in the body does not mean the subject is impaired. Given this reality, the new class of products termed “Impairment Detection Technology” has become critical.
As we look ahead to 2024, I’m deeply optimistic about Gaize. We’re going to continue to execute on our mission with rigor and tenacity. What we’re building is going to save lives and our amazing team is deeply dedicated to building on our success. In the coming months, we’re going to be releasing some improvements to our technology that will make it even more easy to use, more accurate, and more stable. I look forward to revealing more soon!
From all of us at Gaize, Happy New Year!
Ken Fichtler
Founder and CEO
Gaize
